Search

Your search keyword '"Deroose, Christophe M."' showing total 672 results
Start Over Author "Deroose, Christophe M."
672 results on '"Deroose, Christophe M."'

5. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands: version 1.0

Author

Albert, Nathalie L., Preusser, Matthias, Traub-Weidinger, Tatjana, Tolboom, Nelleke, Law, Ian, Palmer, Joshua D., Guedj, Eric, Furtner, Julia, Fraioli, Francesco, Huang, Raymond Y., Johnson, Derek R., Deroose, Christophe M., Herrmann, Ken, Vogelbaum, Michael, Chang, Susan, Tonn, Joerg-Christian, Weller, Michael, Wen, Patrick Y., van den Bent, Martin J., Verger, Antoine, Ivanidze, Jana, and Galldiks, Norbert

Published
2024
Full Text
View/download PDF

9. How to attract young talent to nuclear medicine step 1: a survey conducted by the EANM Oncology and Theranostics Committee to understand the expectations of the next generation

Author

Ambrosini, Valentina, Carrilho Vaz, Sofia, Ahmadi Bidakhvidi, Niloefar, Chanchou, Marion, Cysouw, Matthijs C. F., Serani, Francesca, Voltin, Conrad-Amadeus, Kraeber-Bodere, Francoise, Deroose, Christophe M., De Geus-Oei, Lioe-Fee, Eiber, Matthias, Gnanasegaran, Gopinath, Gotthardt, Martin, Kobe, Carsten, Konijnenberg, Mark W., Nanni, Cristina, Oprea Lager, Daniela E., Rahbar, Kambiz, Taieb, David, Mottaghy, Felix M., Goffin, Karolien, and Herrmann, Ken

Published
2023
Full Text
View/download PDF

11. Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities

Author

Ahire, Vidhula, Ahmadi Bidakhvidi, Niloefar, Boterberg, Tom, Chaudhary, Pankaj, Chevalier, Francois, Daems, Noami, Delbart, Wendy, Baatout, Sarah, Deroose, Christophe M., Fernandez-Palomo, Cristian, Franken, Nicolaas A. P., Gaipl, Udo S., Geenen, Lorain, Heynickx, Nathalie, Koniarová, Irena, Selvaraj, Vinodh Kumar, Levillain, Hugo, Michaelidesová, Anna Jelínek, Montoro, Alegría, Oei, Arlene L., Penninckx, Sébastien, Reindl, Judith, Rödel, Franz, Sminia, Peter, Tabury, Kevin, Vermeulen, Koen, Viktorsson, Kristina, Waked, Anthony, and Baatout, Sarah, editor

Published
2023
Full Text
View/download PDF

14. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study

Author

Strosberg, Jonathan, Kunz, Pamela L, Hendifar, Andrew, Yao, James, Bushnell, David, Kulke, Matthew H, Baum, Richard P, Caplin, Martyn, Ruszniewski, Philippe, Delpassand, Ebrahim, Hobday, Timothy, Verslype, Chris, Benson, Al, Srirajaskanthan, Rajaventhan, Pavel, Marianne, Mora, Jaume, Berlin, Jordan, Grande, Enrique, Reed, Nicholas, Seregni, Ettore, Paganelli, Giovanni, Severi, Stefano, Morse, Michael, Metz, David C, Ansquer, Catherine, Courbon, Frédéric, Al-Nahhas, Adil, Baudin, Eric, Giammarile, Francesco, Taïeb, David, Mittra, Erik, Wolin, Edward, O’Dorisio, Thomas M, Lebtahi, Rachida, Deroose, Christophe M, Grana, Chiara M, Bodei, Lisa, Öberg, Kjell, Polack, Berna Degirmenci, He, Beilei, Mariani, Maurizio F, Gericke, Germo, Santoro, Paola, Erion, Jack L, Ravasi, Laura, and Krenning, Eric

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Alkaline Phosphatase, Humans, Liver Neoplasms, Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Treatment Outcome, NETTER-1 study group, 177Lu-Dotatate, Liver tumour burden, NETTER-1, Neuroendocrine tumour, Other Physical Sciences, Clinical Sciences, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

PurposeTo assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate.MethodsIn the phase 3 NETTER-1 trial, patients with advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or to octreotide LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses of PFS by baseline factors, including liver tumour burden, ALP elevation, and target lesion size, were performed using Kaplan-Meier estimates; hazard ratios (HRs) with corresponding 95% CIs were estimated using Cox regression.ResultsSignificantly prolonged median PFS occurred with 177Lu-Dotatate versus octreotide LAR 60 mg in patients with low ( 50%) liver tumour burden (HR 0.187, 0.216, 0.145), and normal or elevated ALP (HR 0.153, 0.177), and in the presence or absence of a large target lesion (diameter > 30 mm; HR, 0.213, 0.063). Within the 177Lu-Dotatate arm, no significant difference in PFS was observed amongst patients with low/moderate/high liver tumour burden (P = 0.7225) or with normal/elevated baseline ALP (P = 0.3532), but absence of a large target lesion was associated with improved PFS (P = 0.0222). Grade 3 and 4 liver function abnormalities were rare and did not appear to be associated with high baseline liver tumour burden.Conclusions177Lu-Dotatate demonstrated significant prolongation in PFS versus high-dose octreotide LAR in patients with advanced, progressive midgut NET, regardless of baseline liver tumour burden, elevated ALP, or the presence of a large target lesion. Clinicaltrials.gov : NCT01578239, EudraCT: 2011-005049-11.

Published
2020

19. Imaging standardisation in metastatic colorectal cancer: A joint EORTC-ESOI-ESGAR expert consensus recommendation

Author

Unterrainer, Marcus, Deroose, Christophe M., Herrmann, Ken, Moehler, Markus, Blomqvist, Lennart, Cannella, Roberto, Caramella, Caroline, Caruso, Damiano, Chouhan, Manil D., Denecke, Timm, De la Pinta, Carolina, De Geus-Oei, Lioe-Fee, Dulskas, Audrius, Eisenblätter, Michel, Foley, Kieran G., Gourtsoyianni, Sofia, Lecouvet, Frederic E., Lopci, Egesta, Maas, Monique, Obmann, Markus M., Oprea-Lager, Daniela E., Verhoeff, Joost J.C., Santiago, Ines, Terraz, Sylvain, D'Anastasi, Melvin, Regge, Daniele, Laghi, Andrea, Beets-Tan, Regina G.H., Heinemann, Volker, Lordick, Florian, Smyth, Elizabeth C., Ricke, Jens, and Kunz, Wolfgang G.

Published
2022
Full Text
View/download PDF

21. Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer.

Author

Ahmadi Bidakhvidi, Niloefar, Gevaert, Thomas, De Schepper, Maxim, Baldewijns, Marcella, Havinga, Enrique, Deckers, Wies, Laenen, Annouschka, Devos, Gaëtan, Giesen, Alexander, Joniau, Steven, Koole, Michel, Everaerts, Wouter, Deroose, Christophe M., and Goffin, Karolien

Subjects
INTRACLASS correlation, PROSTATE cancer patients, RADICAL prostatectomy, PROSTATE tumors, PROSTATE cancer
Abstract

Purpose: Quantification of PSMA expression via PSMA PET is well-established, however quantification of PSMA via immunohistochemistry (IHC) is not standardized. Our aim was to determine the most optimal PSMA IHC scoring system to quantify PSMA expression with PSMA PET as reference standard. Methods: Primary intermediate- and high-risk prostate cancer patients received an [18F]PSMA-1007 PET/MRI followed by radical prostatectomy. SUVmax, SUVmean and Ki of the prostate tumor was determined. Prostate tumors were stained with anti-PSMA antibodies and scored by 2 readers via 10 IHC scoring systems: histochemical score (H-score), immunoreactivity scorepredominant intensity (IRSpredominant intensity), IRS classificationpredominant intensity, IRSmean intensity, IRS classificationmean intensity, Allred score, predominant expression pattern, Shannon diversity index (SDI), percentage negatively stained cells and total percentage positively stained cells. Spearman's rank correlation coefficients (ρ) were calculated between PET parameters and IHC scoring systems. Interreader agreement for the IHC scoring systems was measured by the intraclass correlation coefficient (ICC). Results: Fifty tumors in 46 patients were analysed. H-score had the best correlation with SUVmax (ρ 0.615 p < 0.0001) and SUVmean (ρ 0.570, p < 0.0001) and the second best correlation with Ki (ρ 0.411, p = 0.0030). SDI had the best correlation with Ki (ρ -0.440, p = 0.0014) and the second best correlation with SUVmax (ρ -0.516, p = 0.0001) and SUVmean (ρ -0.490, p = 0.0003). A moderate interreader agreement was observed for H-score (ICC 0.663, 95% CI 0.495–0.797) and SDI (ICC 0.546, 95% CI 0.354–0.725). Conclusion: H-score had the best correlation with PSMA PET quantification and an acceptable interreader agreement. Therefore, we deem H-score the most optimal PSMA IHC scoring system. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

23. EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders.

Author

Nanni, Cristina, Deroose, Christophe M., Balogova, Sona, Lapa, Constantin, Withofs, Nadia, Subesinghe, Manil, Jamet, Bastien, Zamagni, Elena, Ippolito, Davide, Delforge, Michel, and Kraeber-Bodéré, Francoise

Subjects
PLASMA cell diseases, MULTIPLE myeloma, COMPUTED tomography, MEDICAL personnel, POSITRON emission tomography
Abstract

We provide updated guidance and standards for the indication, acquisition, and interpretation of [18F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [18F]FDG PET/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [18F]FDG PET/CT imaging in routine practice and future research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Prognosis after curative resection of non-metastatic pancreatic neuroendocrine tumors: a retrospective tertiary center study.

Author

Hendrickx, Thomas, Vancanneyt, Justine, Dekervel, Jeroen, Verslype, Chris, Van Melkebeke, Lukas, Van Herpe, Filip, Topal, Halit, Jaekers, Joris, Deroose, Christophe M., Vandecaveye, Vincent, and Rasschaert, Gertjan

Abstract

Background Pancreatic neuroendocrine tumors (pNETs) are rare tumors with heterogeneous outcomes. The aim of our study was to determine the long-term outcome, recurrence patterns, as well as the clinical and pathological factors that impact time-to-recurrence (TTR), recurrence-free survival (RFS), and overall survival (OS) in pNETs treated with curative surgery. Methods Data for all patients who underwent radical surgery with curative intent for nonmetastatic pNETs were obtained from a prospectively maintained database of the University Hospitals Leuven. Data from September 2002 until November 2021 were analyzed retrospectively. Patients with metastatic disease and/or neuro-endocrine carcinoma were excluded. Median follow-up time was calculated using the reverse Kaplan-Meier method. A Cox proportional hazards model was used to assess variables associated with recurrence. Results The study included 128 patients. Only 8 patients (6.3%) had recurrent disease over a median follow up of 44.4 months (interquartile range [IQR] 29.8-74.7). The median TTR was 38.7 months (IQR 18.0-46.2). Univariate analysis showed that multiple endocrine neoplasia type 1 (MEN-1) and R1-status were statistically significant predictors for disease recurrence. Conclusions In our series of patients treated with surgery for non-metastatic, well-differentiated pNETs, recurrence was low at 6.3%. MEN-1 and R1-status were predictors for recurrence in univariate analysis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Standardised lesion segmentation for imaging biomarker quantitation: a consensus recommendation from ESR and EORTC

Author

deSouza, Nandita M., van der Lugt, Aad, Deroose, Christophe M., Alberich-Bayarri, Angel, Bidaut, Luc, Fournier, Laure, Costaridou, Lena, Oprea-Lager, Daniela E., Kotter, Elmar, Smits, Marion, Mayerhoefer, Marius E., Boellaard, Ronald, Caroli, Anna, de Geus-Oei, Lioe-Fee, Kunz, Wolfgang G., Oei, Edwin H., Lecouvet, Frederic, Franca, Manuela, Loewe, Christian, Lopci, Egesta, Caramella, Caroline, Persson, Anders, Golay, Xavier, Dewey, Marc, O’Connor, James P. B., deGraaf, Pim, Gatidis, Sergios, and Zahlmann, Gudrun

Published
2022
Full Text
View/download PDF

27. Value of [68Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature

Author

Deleu, Anne-Leen, Laenen, Annouschka, Decaluwé, Herbert, Weynand, Birgit, Dooms, Christophe, De Wever, Walter, Jentjens, Sander, Goffin, Karolien, Vansteenkiste, Johan, Van Laere, Koen, De Leyn, Paul, Nackaerts, Kristiaan, and Deroose, Christophe M.

Published
2022
Full Text
View/download PDF

29. Radionuclide Therapy Management

Author

Holm, Soren, additional, Gear, Jonathan, additional, Minguez Gabina, Pablo, additional, Ferreira, Kelley, additional, Denis Bacelar, Ana, additional, Armstrong, Ian, additional, MacLean, Joseph, additional, Wendorf, Chloee, additional, Deroose, Christophe M., additional, Zwane-Allen, Phephile, additional, Roldao Pereira, Luisa, additional, Kalle, Patrick, additional, and Fragoso Costa, Pedro, additional

Published
2022
Full Text
View/download PDF

30. Clinical impact of using [18F]AlF‐NOTA‐octreotide PET/CT instead of [68Ga]Ga‐DOTA‐SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial

Author

Leupe, Hannes, primary, Pauwels, Elin, additional, Vandamme, Timon, additional, Van den Broeck, Bliede, additional, Lybaert, Willem, additional, Dekervel, Jeroen, additional, Van Herpe, Filip, additional, Jaekers, Joris, additional, Cleeren, Frederik, additional, Hofland, Johannes, additional, Brouwers, Adrienne, additional, Koole, Michel, additional, Bormans, Guy, additional, Van Cutsem, Eric, additional, Geboes, Karen, additional, Laenen, Annouschka, additional, Verslype, Chris, additional, Stroobants, Sigrid, additional, and Deroose, Christophe M., additional

Published
2024
Full Text
View/download PDF

31. Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers

Author

Fournier, Laure, Costaridou, Lena, Bidaut, Luc, Michoux, Nicolas, Lecouvet, Frederic E., de Geus-Oei, Lioe-Fee, Boellaard, Ronald, Oprea-Lager, Daniela E., Obuchowski, Nancy A, Caroli, Anna, Kunz, Wolfgang G., Oei, Edwin H., O’Connor, James P. B., Mayerhoefer, Marius E., Franca, Manuela, Alberich-Bayarri, Angel, Deroose, Christophe M., Loewe, Christian, Manniesing, Rashindra, Caramella, Caroline, Lopci, Egesta, Lassau, Nathalie, Persson, Anders, Achten, Rik, Rosendahl, Karen, Clement, Olivier, Kotter, Elmar, Golay, Xavier, Smits, Marion, Dewey, Marc, Sullivan, Daniel C., van der Lugt, Aad, deSouza, Nandita M., and European Society of Radiology

Published
2021
Full Text
View/download PDF

32. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres

Author

Levillain, Hugo, Bagni, Oreste, Deroose, Christophe M., Dieudonné, Arnaud, Gnesin, Silvano, Grosser, Oliver S., Kappadath, S. Cheenu, Kennedy, Andrew, Kokabi, Nima, Liu, David M., Madoff, David C., Mahvash, Armeen, Martinez de la Cuesta, Antonio, Ng, David C. E., Paprottka, Philipp M., Pettinato, Cinzia, Rodríguez-Fraile, Macarena, Salem, Riad, Sangro, Bruno, Strigari, Lidia, Sze, Daniel Y., de Wit van der veen, Berlinda J., and Flamen, Patrick

Published
2021
Full Text
View/download PDF

33. Clinical impact of using [18F]AlF‐NOTA‐octreotide PET/CT instead of [68Ga]Ga‐DOTA‐SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial.

Author

Leupe, Hannes, Pauwels, Elin, Vandamme, Timon, Van den Broeck, Bliede, Lybaert, Willem, Dekervel, Jeroen, Van Herpe, Filip, Jaekers, Joris, Cleeren, Frederik, Hofland, Johannes, Brouwers, Adrienne, Koole, Michel, Bormans, Guy, Van Cutsem, Eric, Geboes, Karen, Laenen, Annouschka, Verslype, Chris, Stroobants, Sigrid, and Deroose, Christophe M.

Subjects
POSITRON emission tomography, SOMATOSTATIN receptors, COMPUTED tomography, NEUROENDOCRINE tumors, SECONDARY analysis
Abstract

[18F]AlF‐NOTA‐octreotide ([18F]AlF‐OC) is a promising alternative for [68Ga]Ga‐DOTA‐somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM staging and differences in patient management between [18F]AlF‐OC PET/CT and [68Ga]Ga‐DOTA‐SSA PET/CT in the work‐up of neuroendocrine tumor (NET) patients. Patients who underwent both [18F]AlF‐OC and [68Ga]Ga‐DOTA‐TATE or [68Ga]Ga‐DOTA‐NOC PET/CT in our multicenter study (Pauwels et al., J Nucl Med.2023;63:632–638) with a NET were included for analysis. TNM staging was determined and compared for both tracers. For each patient, the blinded [68Ga]Ga‐DOTA‐SSA or [18F]AlF‐OC PET/CT images were presented in random order at a multidisciplinary team board. The images were presented together with clinical information and compared with previous SSTR and [18F]FDG PET/CT imaging. After a consensus decision for patient management was recorded, the board was presented with the PET/CT images from the other SSTR tracer and a decision was made for the second tracer. Differences in management were classified as major if it entailed an intermodality change and minor if it led to an intramodality change. Compared with [68Ga]Ga‐DOTA‐SSA, the use of [18F]AlF‐OC led to a change in 16/75 patients: TNM staging changes in 10/75 patients (13.3%; downstaging in 3/10, upstaging in 7/10) and differences in clinical management were seen in 10/75 patients (13.3%), leading to a major difference in 7/10 cases and a minor change in 3/10 cases. All 10 cases with a difference in patient management between both PET tracers were caused by additional lesion detection by [18F]AlF‐OC. The use of [18F]AlF‐OC did not impact TNM staging or clinical management in the large majority of the patients (86.7%), further validating the potential for routine clinical use of [18F]AlF‐OC PET/CT as an alternative for [68Ga]Ga‐DOTA‐SSA PET/CT. The trial is registered under ClinicalTrials.gov identifier NCT04552847 and EudraCT 2020–000549‐15. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Clinical management of typical and atypical carcinoids/neuroendocrine tumors in ENETS centres of excellence (CoE): Survey from the ENETS lung NET task force.

Author

Koumarianou, Anna, Filosso, Pier Luigi, Bodei, Lisa, Castano, Justo P., Fernandez‐Cuesta, Lynnette, Deroose, Christophe M., Foll, Matthieu, Dromain, Clarisse, Reed, Nicholas Simon, Caplin, Martyn, Capdevila, Jaume, Falkerby, Jenny, Faggiano, Antongiulio, Frilling, Andrea, Grande, Enrique, Hicks, Rodney J., Kasajima, Atsuko, Kos‐Kudla, Beata, Krishna, B. A., and Lim, Eric

Subjects
NEUROENDOCRINE tumors, MEDICAL personnel, NEUROENDOCRINE cells, TASK forces, LUNGS, CARCINOID
Abstract

Lung carcinoid tumours are neuroendocrine neoplasms originating from the bronchopulmonary tract's neuroendocrine cells, accounting for only 1%–3% of all lung cancers but 30% of all neuroendocrine tumours. The incidence of lung carcinoids, both typical and atypical, has been increasing over the years due to improved diagnostic methods and increased awareness among clinicians and pathologists. The most recent WHO classification includes a subgroup of lung carcinoids with atypical morphology and higher mitotic count and/or Ki67 labelling index. Despite appropriate surgery, the 5‐year survival rate for atypical carcinoids barely exceeds 50%–70%. The role of adjuvant therapy in lung carcinoids is not well‐defined, and clinical decisions are generally based on the presence of high‐risk features. Long‐term follow‐up is essential to monitor for recurrence, although the optimal follow‐up protocol remains unclear. To address the lack of consensus in clinical management decisions, the European Neuroendocrine Tumor Society (ENETS) initiated a survey among 20 expert centres. The survey identified varied opinions on approaches to imaging, surgery, use of adjuvant therapy, and follow‐up protocols. Notably, the absence of dedicated multidisciplinary lung neuroendocrine tumour boards in some centres was evident. Experts agreed on the need for a prospective adjuvant trial in high‐risk patients, emphasizing the feasibility of such a study. In conclusion, the study highlights the need for a more uniform adoption of existing guidelines in the management of lung carcinoid tumours and emphasizes the importance of international collaboration to advance research and patient care. Close collaboration between healthcare providers and patients is vital for effective long‐term surveillance and management of these rare tumours. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Use and perceived utility of [18 F]FDG PET/CT in neuroendocrine neoplasms : A consensus report from the European Neuroendocrine Tumor Society (ENETS) Advisory Board Meeting 2022.

Author

Ambrosini, Valentina, Caplin, Martyn, Castaño, Justo P, Christ, Emanuel, Denecke, Timm, Deroose, Christophe M, Dromain, Clarisse, Falconi, Massimo, Grozinsky-Glasberg, Simona, Hicks, Rodney J, Hofland, Johannes, Kjaer, Andreas, Knigge, Ulrich Peter, Kos-Kudla, Beata, Koumarianou, Anna, Krishna, Balkundi, Lamarca, Angela, Pavel, Marianne, Reed, Nicholas Simon, Scarpa, Aldo, Srirajaskanthan, Rajaventhan, Sundin, Anders, Toumpanakis, Christos, Prasad, Vikas, Ambrosini, Valentina, Caplin, Martyn, Castaño, Justo P, Christ, Emanuel, Denecke, Timm, Deroose, Christophe M, Dromain, Clarisse, Falconi, Massimo, Grozinsky-Glasberg, Simona, Hicks, Rodney J, Hofland, Johannes, Kjaer, Andreas, Knigge, Ulrich Peter, Kos-Kudla, Beata, Koumarianou, Anna, Krishna, Balkundi, Lamarca, Angela, Pavel, Marianne, Reed, Nicholas Simon, Scarpa, Aldo, Srirajaskanthan, Rajaventhan, Sundin, Anders, Toumpanakis, Christos, and Prasad, Vikas

Abstract

Somatostatin receptor (SST) PET/CT is the gold standard for well-differentiated neuroendocrine tumours (NET) imaging. Higher grades of neuroendocrine neoplasms (NEN) show preferential [18F]FDG (FDG) uptake, and even low-grade NET may de-differentiate over time. FDG PET/CT's prognostic role is widely accepted; however, its impact on clinical decision-making remains controversial and its use varies widely. A questionnaire-based survey on FDG PET/CT use and perceived decision-making utility in NEN was submitted to the ENETS Advisory Board Meeting attendees (November 2022, response rate = 70%). In 3/15 statements, agreement was higher than 75%: (i) FDG was considered useful in NET, irrespective of grade, in case of mis-matched lesions (detectable on diagnostic CT but negative/faintly positive on SST PET/CT), especially if PRRT is contemplated (80%); (ii) in NET G3 if curative surgery is considered (82%); and (iii) in NEC prior to surgery with curative intent (98%). FDG use in NET G3, even in the presence of matched lesions, as a baseline for response assessment was favoured by 74%. Four statements obtained more than 60% consensus: (i) FDG use in NET G3 if locoregional therapy is considered (65%); (ii) in neuroendocrine carcinoma before initiating active therapy as a baseline for response assessment (61%); (iii) biopsy to re-assess tumour grade prior to a change in therapeutic management (68%) upon detection of FDG-positivity on the background of a prior G1-2 NET; (iv) 67% were in favour to reconsider PRRT to treat residual SST-positive lesions after achieving complete remission on FDG of the SST-negative disease component. Multidisciplinary opinion broadly supports the use of FDG PET/CT for characterisation of disease biology and to guide treatment selection across a range of indications, despite the lack of full consensus in many situations. This may reflect existing clinical access due to lack of reimbursement or experience with this investigation, which should be add

Published
2024
Full Text
View/download PDF

37. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor ligands:version 1.0

Author

Albert, Nathalie L., Preusser, Matthias, Traub-Weidinger, Tatjana, Tolboom, Nelleke, Law, Ian, Palmer, Joshua D., Guedj, Eric, Furtner, Julia, Fraioli, Fracesco, Huang, Raymond Y., Johnson, Derek R., Deroose, Christophe M., Hermann, Ken, Vogelbaum, Michael, Chang, Susan, Tonn, Joerg-Christian, Weller, Michael, Wen, Patrick Y., van den Bent, Martin J., Verger, Antoine, Ivanidze, Jana, Galldiks, Norbert, Albert, Nathalie L., Preusser, Matthias, Traub-Weidinger, Tatjana, Tolboom, Nelleke, Law, Ian, Palmer, Joshua D., Guedj, Eric, Furtner, Julia, Fraioli, Fracesco, Huang, Raymond Y., Johnson, Derek R., Deroose, Christophe M., Hermann, Ken, Vogelbaum, Michael, Chang, Susan, Tonn, Joerg-Christian, Weller, Michael, Wen, Patrick Y., van den Bent, Martin J., Verger, Antoine, Ivanidze, Jana, and Galldiks, Norbert

Abstract

Purpose To provide practice guideline/procedure standards for diagnostics and therapy (theranostics) of meningiomas using radiolabeled somatostatin receptor (SSTR) ligands.Methods This joint practice guideline/procedure standard was collaboratively developed by the European Association of Nuclear Medicine (EANM), the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Neurooncology (EANO), and the PET task force of the Response Assessment in Neurooncology Working Group (PET/RANO).Results Positron emission tomography (PET) using somatostatin receptor (SSTR) ligands can detect meningioma tissue with high sensitivity and specificity and may provide clinically relevant information beyond that obtained from structural magnetic resonance imaging (MRI) or computed tomography (CT) imaging alone. SSTR-directed PET imaging can be particularly useful for differential diagnosis, delineation of meningioma extent, detection of osseous involvement, and the differentiation between posttherapeutic scar tissue and tumour recurrence. Moreover, SSTR-peptide receptor radionuclide therapy (PRRT) is an emerging investigational treatment approach for meningioma.Conclusion These practice guidelines will define procedure standards for the application of PET imaging in patients with meningiomas and related SSTR-targeted PRRTs in routine practice and clinical trials and will help to harmonize data acquisition and interpretation across centers, facilitate comparability of studies, and to collect larger databases. The current document provides additional information to the evidence-based recommendations from the PET/RANO Working Group regarding the utilization of PET imaging in meningiomas Galldiks (Neuro Oncol. 2017;19(12):1576-87). The information provided should be considered in the context of local conditions and regulations.

Published
2024

40. Impact of the COVID-19 crisis on imaging in oncological trials

Author

Deroose, Christophe M., Lecouvet, Frédéric E., Collette, Laurence, Oprea-Lager, Daniela E., Kunz, Wolfgang G., Bidaut, Luc, Verhoeff, Joost J. C., Caramella, Caroline, Lopci, Egesta, Tombal, Bertrand, de Geus-Oei, Lioe-Fee, Fournier, Laure, Smits, Marion, and deSouza, Nandita M.

Published
2020
Full Text
View/download PDF

44. Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group

Author

Lecouvet, Frédéric E, Oprea-Lager, Daniela E, Liu, Yan, Ost, Piet, Bidaut, Luc, Collette, Laurence, Deroose, Christophe M, Goffin, Karolien, Herrmann, Ken, Hoekstra, Otto S, Kramer, Gem, Lievens, Yolande, Lopci, Egesta, Pasquier, David, Petersen, Lars J, Talbot, Jean-Noël, Zacho, Helle, Tombal, Bertrand, and deSouza, Nandita M

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results